These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25086190)

  • 1. Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients.
    Wolf WA; Cotton CC; Green DJ; Hughes JT; Woosley JT; Shaheen NJ; Dellon ES
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):452-8. PubMed ID: 25086190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of major basic protein, eotaxin-3, and mast cell tryptase staining for prediction of response to topical steroid treatment in eosinophilic esophagitis: analysis of a randomized, double-blind, double dummy clinical trial.
    Dellon ES; Woosley JT; McGee SJ; Moist SE; Shaheen NJ
    Dis Esophagus; 2020 Jun; 33(6):. PubMed ID: 32193541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study.
    Dellon ES; Speck O; Woodward K; Covey S; Rusin S; Gebhart JH; Chen X; Woosley JT; Shaheen NJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2015-22. PubMed ID: 24993367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and gene expression analysis of initial biopsies from patients with eosinophilic esophagitis refractory to therapy.
    Siddique AS; Corney DC; Mangray S; Lombardo KA; Chen S; Marwaha AS; Resnick MB; Herzlinger M; Matoso A
    Hum Pathol; 2017 Oct; 68():79-86. PubMed ID: 28882697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher Body Mass Index Is Associated With Decreased Treatment Response to Topical Steroids in Eosinophilic Esophagitis.
    Ketchem CJ; Ocampo AA; Xue Z; Chang NC; Thakkar KP; Reddy S; Greenberg SB; Lee CJ; Redd WD; Eluri S; Reed CC; Dellon ES
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2252-2259.e3. PubMed ID: 36410644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Evaluation of Noninvasive Biomarkers for Eosinophilic Esophagitis.
    Min SB; Nylund CM; Baker TP; Ally M; Reinhardt B; Chen YJ; Nazareno L; Moawad FJ
    J Clin Gastroenterol; 2017 Feb; 51(2):127-135. PubMed ID: 27479142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of Fluticasone to Budesonide in the Treatment of Eosinophilic Esophagitis.
    Albert D; Heifert TA; Min SB; Maydonovitch CL; Baker TP; Chen YJ; Moawad FJ
    Dig Dis Sci; 2016 Jul; 61(7):1996-2001. PubMed ID: 27093866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Molecular Factors Associated With Histologic Response to Topical Steroid Treatment in Patients With Eosinophilic Esophagitis.
    Eluri S; Selitsky SR; Perjar I; Hollyfield J; Betancourt R; Randall C; Rusin S; Woosley JT; Shaheen NJ; Dellon ES
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1081-1088.e2. PubMed ID: 30213583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis.
    Runge TM; Eluri S; Woosley JT; Shaheen NJ; Dellon ES
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 29206905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Swallowed Fluticasone Propionate Is an Effective Long-Term Maintenance Therapy for Children With Eosinophilic Esophagitis.
    Andreae DA; Hanna MG; Magid MS; Malerba S; Andreae MH; Bagiella E; Chehade M
    Am J Gastroenterol; 2016 Aug; 111(8):1187-97. PubMed ID: 27325220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Esophageal Dilation in Eosinophilic Esophagitis: Safety, Efficacy, and Persistence of the Fibrostenotic Phenotype.
    Runge TM; Eluri S; Cotton CC; Burk CM; Woosley JT; Shaheen NJ; Dellon ES
    Am J Gastroenterol; 2016 Feb; 111(2):206-13. PubMed ID: 26753894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distal esophagus is the most commonly involved site for strictures in patients with eosinophilic esophagitis.
    Eluri S; Tappata M; Huang KZ; Koutlas NT; Robey BS; Fan C; Reed CC; Shaheen NJ; Dellon ES
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31778150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Histologic Cutpoints for Treatment Response in Patients With Eosinophilic Esophagitis: Analysis of Data From a Prospective Cohort Study.
    Reed CC; Wolf WA; Cotton CC; Rusin S; Perjar I; Hollyfield J; Woosley JT; Shaheen NJ; Dellon ES
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):226-233.e2. PubMed ID: 28987502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids.
    Rajan J; Newbury RO; Anilkumar A; Dohil R; Broide DH; Aceves SS
    J Allergy Clin Immunol; 2016 Jan; 137(1):147-156.e8. PubMed ID: 26233926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis.
    Eluri S; Runge TM; Cotton CC; Burk CM; Wolf WA; Woosley JT; Shaheen NJ; Dellon ES
    Gastrointest Endosc; 2016 Jun; 83(6):1142-8. PubMed ID: 26608127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of topical steroids on tight junction proteins and spongiosis in esophageal epithelia of patients with eosinophilic esophagitis.
    Katzka DA; Tadi R; Smyrk TC; Katarya E; Sharma A; Geno DM; Camilleri M; Iyer PG; Alexander JA; Buttar NS
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1824-9.e1. PubMed ID: 24681080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis.
    Kuchen T; Straumann A; Safroneeva E; Romero Y; Bussmann C; Vavricka S; Netzer P; Reinhard A; Portmann S; Schoepfer AM
    Allergy; 2014 Sep; 69(9):1248-54. PubMed ID: 24894658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD25, mast cell markers and T-cell markers in eosinophilic esophagitis.
    Htoo A; Qualia CM; George R; Arker SH; Subasi NB; Lee H; Chung L; Chen A
    Ann Diagn Pathol; 2024 Jun; 70():152287. PubMed ID: 38479198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Older patients with eosinophilic esophagitis have high treatment response to topical steroids.
    Ketchem CJ; Thakkar KP; Xue A; Reddy S; Abramson L; Greenberg SB; Abichandani S; Miller TL; Chang NC; Eluri S; Reed CC; Dellon ES
    Dig Liver Dis; 2022 Apr; 54(4):477-482. PubMed ID: 34789398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum eosinophil cationic protein is superior to mast cell tryptase as marker for response to topical corticosteroid therapy in eosinophilic esophagitis.
    Schlag C; Pfefferkorn S; Brockow K; Haller B; Slotta-Huspenia J; Schulz S; von Werder A; Ring J; Schmid RM; Bajbouj M
    J Clin Gastroenterol; 2014 Aug; 48(7):600-6. PubMed ID: 24177377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.